February 8, 2018 : Latest SGLT-2 Inhibitors News

• How Does Empagliflozin Reduce Cardiovascular Mortality In Type 2 Patients, Including Those With PAD?
• Controversy Between SGLT-2 Inhibitors and GLP-1 Agonists as Preferred Second-Line Therapy
• Study Shows Advantage of SGLT2’s Over DPP-4’s
• Exclusive Interview: Ray Kausik Part 4, PCSK9 And SGLT-2 Combination Therapy

For years we only had three ways to manage diabetes besides insulin, but in the last decade we have added four new classes of drugs. It only makes sense that there would be studies to compare the new drug choices. Oftentimes the manufacturers themselves fund the studies. However, in this week’s special edition we look at the literature available from unbiased sources to help you make the right decisions.

Dave Joffe

Editor-in-chief

The answer comes from a mediation analysis of the EMPA-REG OUTCOME Trial.

Patient specific considerations have to be taken into account prior to choosing GLP-1 agonist or SGLT2 inhibitor as second-line anti-hyperglycemic agent.

Systematic review and meta-analysis show lead in HbA1c reduction, weight loss, and favorable fasting blood glucose levels.

In part 4 of this Exclusive Interview, Dr. Ray Kausik talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 convention in San Diego, CA about the joint effects of SGLT-2 and PCSK9 inhibitors.